Department of Preventive and Social Medicine, Hugh Adam Cancer Epidemiology Unit, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand.
Br J Cancer. 2010 May 25;102(11):1665-9. doi: 10.1038/sj.bjc.6605675. Epub 2010 Apr 20.
We investigated whether elevation in serum cytomegalovirus (CMV) or Epstein-Barr virus (EBV) immunoglobulin G (IgG) antibody levels precedes the development of breast cancer.
A nested case-control study was carried out within the Janus Serum Bank cohort. Two serum samples, one taken at least 4 years before diagnosis (sample 2) and an earlier sample (sample 1) from 399 women with invasive breast cancer and from 399 controls, matched for date of blood samples and age were tested for CMV and EBV IgG antibodies. Odds ratios (ORs) with 95% confidence intervals (CIs) for CMV and EBV seroconversion between the samples and unit changes in IgG optical density (OD) examined as a continuous variable were calculated using conditional logistic regression.
Eleven cases and three controls seroconverted for CMV IgG between the first and second blood samples, with an adjusted OR for CMV IgG seroconversion of 4.0 (95% CI=1.1-14.4). The risk of breast cancer, adjusted for parity, increased per unit difference in CMV OD between samples (OR=1.7, 95% CI=1.1-2.5). In an analysis restricted to parous cases and age-matched parous controls, the OR for CMV seroconversion for IgG between the two samples, adjusted for parity and age at first birth, was 9.7 (95% CI=1.2-77.3). The EBV seroconversion or change in EBV OD was not associated with risk of breast cancer.
Our hypothesis that elevation in serum CMV IgG antibody levels precedes the development of breast cancer in some women is supported by the results of this study. Changes in EBV IgG antibody are not associated with risk of breast cancer.
我们研究了血清巨细胞病毒（CMV）或 Epstein-Barr 病毒（EBV）免疫球蛋白 G（IgG）抗体水平升高是否先于乳腺癌的发生。
在 Janus 血清库队列中进行了一项巢式病例对照研究。从 399 名浸润性乳腺癌患者和 399 名匹配的对照者中，选取 399 名患者的两个血清样本，一个在诊断前至少 4 年采集（样本 2），另一个为较早的样本（样本 1）。检测 CMV 和 EBV IgG 抗体。采用条件逻辑回归计算两个样本之间 CMV 和 EBV IgG 血清转化率的比值比（OR）及其 95%置信区间（CI），并将 IgG 光密度（OD）的单位变化作为连续变量进行检验。
11 例患者和 3 例对照者在第一和第二份血样之间发生 CMV IgG 血清转化，CMV IgG 血清转化的调整 OR 为 4.0（95%CI=1.1-14.4）。调整了产次后，CMV OD 样本间每单位差异与乳腺癌风险增加相关（OR=1.7，95%CI=1.1-2.5）。在仅包括产褥期病例和年龄匹配的产褥期对照者的分析中，调整产次和初产妇年龄后，两个样本间 CMV IgG 血清转化的 OR 为 9.7（95%CI=1.2-77.3）。EBV IgG 血清转化或 EBV OD 变化与乳腺癌风险无关。
本研究结果支持我们的假设，即血清 CMV IgG 抗体水平升高先于某些女性乳腺癌的发生。EBV IgG 抗体的变化与乳腺癌风险无关。
